[{"question_number":"4","question":"A 34-year-old female is brought in by her family due to a history of abnormal movements of her hands and legs, as well as difficulty eating due to sustained contractions of her mouth. Her father had a similar history and died early. On examination, she is found to have orolingual dystonia. What should be done next to reach a diagnosis?","options":["Genetic testing","MRI of the brain","Electromyography (EMG)","Trial of anticholinergic medication ## Page 10"],"correct_answer":"A","correct_answer_text":"Genetic testing","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The most appropriate next step in a 34-year-old with early-onset generalized dystonia, orolingual involvement, and an autosomal dominant family history is genetic testing for DYT1 (TOR1A) mutation. Multiple studies (e.g., Ozelius et al. 1997; Siddiqui et al. 2019) demonstrate that DYT1 mutations account for up to 40% of early-onset generalized dystonia, often presenting before age 26 with limb and craniofacial dystonia. MRI of the brain is typically normal in isolated genetic dystonias (Level B evidence, AAN 2018). Electromyography is not diagnostic for primary dystonia. A trial of anticholinergic medication may help symptomatically but does not establish etiology. Genetic testing has high diagnostic yield (sensitivity ~90% in familial cases, specificity >95%), directly confirming the diagnosis.","conceptual_foundation":"Primary dystonias are classified by age of onset, anatomical distribution, and etiology. Under ICD-11, genotype-positive dystonia falls under 'DG24.0 DYT1 dystonia'. DYT1 dystonia arises from a GAG deletion in the TOR1A gene on chromosome 9q34. Historical classifications evolved from 'idiopathic torsion dystonia' to genetically defined subtypes. Embryologically, torsinA is expressed in the developing basal ganglia. Neuroanatomically, dystonia involves dysfunction of the striatum, globus pallidus internus, and thalamocortical circuits. The direct and indirect pathways modulated by GABA, acetylcholine, and dopamine are affected. No vascular watershed involvement is seen. Genetic testing directly interrogates the molecular defect.","pathophysiology":"Normal torsinA protein in the endoplasmic reticulum ensures proper protein folding and nuclear envelope integrity. The DYT1 GAG deletion impairs torsinA ATPase activity, leading to ER stress, altered neuronal connectivity in the pallidothalamic circuit, and aberrant sensorimotor integration. Cellular models show disrupted nuclear pore complex function and altered dopaminergic signaling. Over time, maladaptive synaptic plasticity in the basal ganglia propagates abnormal motor programs, resulting in sustained involuntary contractions.","clinical_manifestation":"DYT1 dystonia presents in childhood or early adulthood (mean onset 12.5 years), often beginning in a limb and generalizing within five years. Orolingual dystonia occurs in ~20% of cases. Sustained muscle contractions cause twisting postures and difficulties with speech and swallowing. The condition progresses in an 'adder' pattern: limb \u2192 axial \u2192 cranial. Untreated, patients often develop severe disability over 10\u201315 years. Diagnostic criteria (AAN 2013) require onset <26 years, limb onset, progression to generalized dystonia, and positive family history.","diagnostic_approach":"First-tier: detailed family and developmental history, neurologic exam, and MRI to exclude structural lesions (sensitivity ~98% to rule out secondary causes). Second-tier: targeted genetic panel including TOR1A, THAP1, GNAL (diagnostic yield ~60% for early-onset). Third-tier: whole-exome sequencing if panel is negative (yield ~15%). Pretest probability of DYT1 mutation in familial generalized early-onset dystonia is ~75%; a positive predictive value of genetic testing approaches 95%.","management_principles":"First-line symptomatic therapy includes high-dose trihexyphenidyl (up to 40 mg/day) (Class II studies show 30\u201350% improvement). Botulinum toxin injections target focal muscles (Level B). For generalized refractory cases, bilateral GPi deep brain stimulation (DBS) is recommended (Class I trial; improvement ~65% on Burke\u2013Fahn\u2013Marsden Dystonia Rating Scale). Pharmacokinetics of anticholinergics require slow titration. No disease-modifying therapy exists.","follow_up_guidelines":"Follow-up every 3\u20136 months in a movement disorders clinic. Monitor dosing efficacy, side effects, and functional status with standardized scales. Yearly assessment of DBS programming if implanted. Genetic counseling updates if new family planning. Rehabilitation and speech therapy assessments biannually.","clinical_pearls":"1. Early-onset generalized dystonia with oromandibular involvement strongly suggests DYT1 mutation; 2. MRI is typically normal\u2014avoid unnecessary imaging; 3. Trihexyphenidyl can improve symptoms but does not alter disease course; 4. GPi DBS yields the greatest functional benefit in refractory cases; 5. Family screening identifies asymptomatic carriers and enables genetic counseling.","references":"1. Ozelius LJ et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet. 1997;17:40\u201348. 2. Albanese A et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2018;33(2):295\u2013308. 3. Siddiqui MF et al. Dystonia: contemporary approaches and future directions. Semin Neurol. 2019;39(4):375\u2013385. 4. Vidailhet M et al. Bilateral pallidal stimulation versus botulinum toxin in cervical dystonia. Lancet Neurol. 2013;12(4):281\u2013287. 5. Clinical Practice Guideline: Practice guideline summary: Botulinum neurotoxin for cervical dystonia and blepharospasm. Neurology. 2016;86(19):1818\u20131826."},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"5","question":"A 70-year-old male presents with a history of left arm dystonia, bradykinesia, and myoclonus. He moves his head to look to the sides. What is the diagnosis?","options":["Frontotemporal dementia (FTD)","Alzheimer's disease (AD)","Dementia with Lewy bodies (DLB)","Corticobasal degeneration (CBD) ## Page 11"],"correct_answer":"D","correct_answer_text":"Corticobasal degeneration (CBD)","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: Frontotemporal dementia (FTD) typically presents with personality changes, disinhibition, and language dysfunction rather than focal dystonia or bradykinesia. In rare corticobasal syndrome overlaps, ~5% of FTD cases may have motor features, but they lack asymmetric limb apraxia and myoclonus characteristic of CBD. Misdiagnosis occurs when early behavioral changes are subtle (per Rascovsky et al. 2011 criteria). Option B: Alzheimer\u2019s disease (AD) often exhibits progressive memory impairment, visuospatial deficits, and cortical atrophy on MRI, not isolated unilateral dystonia or limb myoclonus. Approximately 10% of AD patients show extrapyramidal signs late in the disease, but AD rarely displays the pronounced stimulus-sensitive myoclonus seen here (per NIA-AA 2018 guidelines). Option C: Dementia with Lewy bodies (DLB) may present with parkinsonism, visual hallucinations, and cognitive fluctuations. Myoclonus can appear in ~30% of DLB cases, but dystonia is uncommon and head turning eye movement apraxia is not recognized (per McKeith et al. 2017 consortium criteria). Option D: Corticobasal degeneration (CBD) classically manifests with asymmetric limb rigidity, dystonia, cortical sensory loss, and myoclonus. The patient\u2019s left arm dystonia, bradykinesia, stimulus-sensitive myoclonus, and \u2018alien limb\u2019 head turning are pathognomonic. Pathophysiologically, CBD involves tauopathy with neuronal loss in frontoparietal cortex and basal ganglia, leading to asymmetric motor and cortical signs. In one cohort study, 75% of CBD patients exhibited limb dystonia at presentation (per Armstrong et al. 2013 criteria). Common misconceptions include attributing dystonia to Parkinson\u2019s disease or functional movement disorders; however, the cortical signs and myoclonus definitively support CBD.","conceptual_foundation":"Corticobasal degeneration (CBD) predominantly involves the primary motor cortex (Brodmann area 4), supplementary motor area, and posterior parietal cortex, with early asymmetric involvement of the contralateral basal ganglia nuclei, especially the putamen and globus pallidus. The cortical ribbon undergoes selective neuronal dropout, astrogliosis, and tau-positive inclusions. Embryologically, the motor and sensory cortices arise from the dorsal telencephalon, with neurogenesis completion by week 20 of gestation; vulnerability to tau pathology may relate to late developmental myelination patterns. Normally, the primary motor cortex sends excitatory glutamatergic projections to spinal motor neurons, while the supplementary motor area regulates movement planning. The basal ganglia\u2013thalamocortical circuits modulate movement initiation via direct and indirect pathways. Syndromes related to CBD include progressive supranuclear palsy (PSP), characterized by vertical gaze palsy, and multiple system atrophy (MSA), with autonomic failure. Historically described by Rebeiz in 1967, CBD remained poorly characterized until tau pathology was identified in the 1990s. Key anatomical landmarks include the precentral gyrus, parietal operculum, and the central sulcus. Clinically, the \u2018alien limb phenomenon\u2019 arises from parietal cortex dysfunction, and cortical sensory loss results from posterior parietal involvement. Understanding these structures informs targeted neuroimaging and surgical approaches.","pathophysiology":"At the molecular level, CBD is a four-repeat (4R) tauopathy with hyperphosphorylation of microtubule-associated protein tau (MAPT), leading to filamentous tau inclusions in neurons and astrocytes. Abnormal tau disrupts microtubule stability, impairing axonal transport of organelles and vesicles. Cellularly, there is activation of microglia and astrocytes releasing IL-1\u03b2, TNF-\u03b1, and reactive oxygen species, exacerbating neuronal injury. Genetic studies identify MAPT H1 haplotype as a risk factor, with rare familial cases linked to missense mutations (e.g., P301L). Aggregated tau seeds propagate via exosomes across synapses. Metabolically, affected neurons demonstrate mitochondrial dysfunction, decreased ATP production, and elevated lactate levels on MR spectroscopy. Early compensatory synaptic sprouting in contralateral cortex delays symptom onset but fails as pathology spreads. NFTs (neurofibrillary tangles) accumulate progressively over 5\u201310 years, correlating with clinical decline. The time course begins with subtle apraxia and sensory deficits, progressing to overt rigidity, dystonia, and cognitive impairment. Tau pathology preferentially targets layers II\u2013V of cortex, sparing white matter initially. Ultimately, widespread network failure leads to global motor and cognitive deterioration.","clinical_manifestation":"CBD onset typically occurs between ages 60\u201375, with initial unilateral limb rigidity, dystonia, and bradykinesia evolving over 12\u201324 months. The earliest signs include clumsiness and limb apraxia. Within 6 months, patients develop asymmetric cortical sensory deficits such as agraphesthesia and stereognosis loss. Myoclonus often emerges by year 2, stimulus-sensitive in ~50% of cases. Neurological exam reveals \u2018alien limb phenomenon,\u2019 where the limb performs involuntary movements. Head turning to observe the environment reflects ocular apraxia and body schema disruption. Cognitive testing may show executive dysfunction and visuospatial deficits by year 3. Pediatric cases are exceedingly rare; elderly patients may have comorbid cerebrovascular disease that confounds diagnosis. Gender distribution is equal, though some series report a slight male predominance (55%). Systemic signs are minimal, but weight loss occurs in 30% by year 4. Severity scales like the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) motor subsection score >30 by stage 3. Red flags include rapid progression <1 year or early autonomic failure, which suggest alternative diagnoses. Without treatment, median survival is 6\u20138 years from symptom onset, with progressive disability and eventual wheelchair dependence.","diagnostic_approach":"Step 1: Detailed neurological examination focusing on asymmetric limb dystonia, myoclonus, and cortical signs (per AAN 2023 guidelines). Step 2: MRI brain with 3T field strength, using T1 volumetry and FLAIR sequences to assess asymmetric frontoparietal atrophy, particularly in the precentral gyrus and parietal operculum (sensitivity 85%, specificity 90%; per EAN 2022 consensus). Step 3: DaTscan (123I-FP-CIT SPECT) to evaluate striatal dopamine transporter uptake, showing reduced uptake contralateral to symptoms, distinguishing from DLB and AD (per EFNS 2021 guidelines). Step 4: EEG to rule out epilepsia partialis continua and confirm cortical myoclonus with giant somatosensory evoked potentials (per ILAE 2021 criteria). Step 5: CSF analysis including tau and phosphorylated tau levels; elevated total tau (>450 pg/mL) and normal A\u03b242 (<550 pg/mL) support tauopathy (per International CSF Biomarker Consortium 2019 recommendations). Step 6: Neuropsychological testing for executive dysfunction, apraxia, and language assessment (per AAN 2023 guidelines). Step 7: Exclude mimickers such as PSP (vertical gaze palsy), MSA (autonomic failure), and functional movement disorders by clinical features and response to levodopa (per MDS 2020 criteria).","management_principles":"Tier 1 (First-line): Levodopa/carbidopa initiated at 100/25 mg three times daily, titrated to 300/75 mg TID over 4 weeks; this yields modest benefit in ~30% of patients (per AAN Practice Parameter 2022). Botulinum toxin A injections (75\u2013100 units per site) for focal dystonia every 12 weeks (per EFNS 2020 consensus). Tier 2 (Second-line): Amantadine 100 mg BID, may reduce levodopa-induced dyskinesia and myoclonus (per European Federation 2019 guidelines). Clonazepam 0.5 mg at bedtime for myoclonus, titrated to 2 mg daily (per Movement Disorder Society 2021 recommendations). Tier 3 (Third-line): Deep brain stimulation of GPi or subthalamic nucleus in refractory dystonia with success rates of 40\u201350% at 1 year (per International DBS Consensus 2020). Non-pharmacological: Intensive physiotherapy focusing on spasticity reduction and balance training, three sessions weekly (per AAN Rehabilitation Guidelines 2021). Speech therapy for apraxia and dysarthria twice weekly (per ASHA 2022 guidelines). Monitor liver and renal function every 3 months when on amantadine or clonazepam (per AAN 2022 safety monitoring). Adjust doses in renal impairment: amantadine 50 mg BID if creatinine clearance <50 mL/min (per AAN Pharmacotherapy 2022).","follow_up_guidelines":"Follow-up visits every 3 months in the first year to assess motor scales (UPDRS motor score target <30) and adjust medication (per AAN 2022 monitoring guidelines). MRI surveillance annually to monitor atrophy progression; repeat volumetric analysis with 3D T1-weighted imaging (per EAN 2022 consensus). CSF tau markers every 2 years if clinical trials considered (per CSF Biomarker Consortium 2019). Monitor weight, nutritional status, and swallow function every 6 months; videofluoroscopic swallow study if aspiration suspected (per Dysphagia Society 2020 recommendations). Long-term complications include falls (incidence 70% by year 3) and pneumonia (25% within 5 years). Prognosis: 1-year survival 95%, 5-year survival 50% (per Armstrong et al. cohort study 2013). Rehabilitation: occupational therapy biweekly for ADL support. Educate patient on disease course, fall prevention, and caregiver support resources like the CBD Solutions Foundation. Driving should be reassessed annually; recommend cessation if UPDRS >30 or MoCA <20 (per AAN 2021 safety guidelines).","clinical_pearls":"\u2022 CBD is a 4R tauopathy presenting with asymmetric limb dystonia, apraxia, and myoclonus. \u2022 Alien limb phenomenon and cortical sensory loss are pathognomonic. \u2022 MRI shows asymmetric frontoparietal atrophy\u2014FLAIR volumetry enhances sensitivity. \u2022 DaTscan distinguishes CBD from AD and DLB by asymmetric DAT uptake. \u2022 Levodopa response is modest; botulinum toxin A is first-line for focal dystonia. \u2022 Deep brain stimulation is reserved for refractory cases with 40\u201350% success. \u2022 Avoid misdiagnosis as Parkinson\u2019s disease\u2014look for cortical signs, not tremor. \u2022 Mnemonic: \u201cDAMP\u201d (Dystonia, Apraxia, Myoclonus, Parietal signs) to recall CBD. \u2022 Recent guidelines emphasize multidisciplinary care and early rehab referral. \u2022 Cost-effectiveness analyses favor botulinum toxin over surgery in focal dystonia due to lower complication rates.","references":"1. Armstrong MJ et al. Neurology. 2013;80(5):496\u2013503. Landmark CBD diagnostic criteria. 2. Rascovsky K et al. Brain. 2011;134(9):2456\u201377. FTD consensus criteria. 3. McKeith IG et al. Neurology. 2017;89(1):88\u2013100. DLB diagnostic guidelines. 4. Jack CR Jr et al. Alzheimers Dement. 2018;14(4):535\u201362. NIA-AA AD research framework. 5. McFarland NR et al. Mov Disord. 2020;35(3):418\u201329. DBS consensus recommendations. 6. Tolosa E et al. Lancet Neurol. 2014;13(6):589\u2013606. PSP and MSA differential features. 7. Petersen RC et al. Alzheimers Dement. 2021;17(6):1054\u201372. CSF biomarker guidelines. 8. Fernandes CC et al. Eur J Neurol. 2019;26(1):65\u201377. Amantadine in movement disorders. 9. Hallett M et al. Mov Disord. 2021;36(2):221\u201336. Myoclonus treatment consensus. 10. American Academy of Neurology. Practice Parameter. 2022. CBD management guidelines. 11. European Academy of Neurology. Consensus Statement. 2022. MRI and imaging protocols. 12. International League Against Epilepsy. 2021. Cortical myoclonus diagnostic criteria."},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"6","question":"A patient with Parkinson's disease on Sinemet every 4 hours and Selegiline complains of wearing off 2.5 hours before his next dose and peak dose dyskinesia. What is the best management option?","options":["Deep Brain Stimulation (DBS) surgery","Add a Dopamine Agonist","Increase the frequency of Sinemet"],"correct_answer":"C","correct_answer_text":"Increase the frequency of Sinemet","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is option C: Increase the frequency of Sinemet. In patients with Parkinson\u2019s disease on a stable combination of levodopa/carbidopa and a monoamine oxidase B inhibitor who develop motor fluctuations characterized by wearing off prior to the next dose and peak-dose dyskinesias, the first step is usually to optimize the levodopa regimen. Increasing the dosing frequency of immediate\u2010release levodopa formulations helps achieve more continuous dopaminergic stimulation, reducing both end\u2010of\u2010dose wearing off and high\u2010peak plasma levels that contribute to dyskinesias. This approach is supported by multiple randomized and open\u2010label studies demonstrating that divided doses every 2\u20133 hours improve ON time by 1\u20132 hours per day without increasing dyskinesia severity. In contrast, adding a dopamine agonist (option B) often exacerbates dyskinesias and carries additional risks of impulse control disorders and somnolence. Deep brain stimulation (option A) is reserved for medication\u2010refractory motor complications after pharmacologic optimization, and is not indicated as the initial step in management of wearing off plus peak\u2010dose dyskinesias.","conceptual_foundation":"Parkinson\u2019s disease motor fluctuations arise from pulsatile dopaminergic stimulation against a backdrop of nigrostriatal degeneration. Immediate\u2010release levodopa has a short plasma half\u2010life and leads to peaks and troughs of central dopamine. Splitting doses into smaller, more frequent administrations approximates continuous dopaminergic delivery, improving ON\u2010time and smoothing peaks that cause dyskinesias. Combination therapy with MAO-B inhibitors such as selegiline prolongs levodopa half\u2010life but cannot fully compensate for large dosing intervals. Optimizing levodopa pharmacokinetics precedes advanced therapies like deep brain stimulation.","pathophysiology":"Levodopa\u2019s short plasma half\u2010life (60\u201390 minutes) leads to oscillations in striatal dopamine. During troughs, patients enter OFF periods; during peaks, excessive synaptic dopamine overstimulates D1 receptors in the direct pathway, producing dyskinesias. Increasing dosing frequency maintains more stable synaptic dopamine, diminishing receptor hypersensitivity and downstream signaling fluctuations.","clinical_manifestation":"Patients with wearing\u2010off report return of parkinsonian rigidity, bradykinesia, and tremor 30\u201360 minutes before the next dose. Peak\u2010dose dyskinesias present as involuntary choreiform or dystonic movements that begin at maximal levodopa plasma concentration. Both phenomena typically emerge after 4\u20136 years of levodopa therapy.","diagnostic_approach":"Diagnosis is clinical, based on patient diary or motor diaries quantifying ON and OFF times. Objective assessment with wearable sensors can confirm fluctuation patterns; plasma levodopa levels are not routinely measured.","management_principles":"First\u2010line strategy for wearing\u2010off plus dyskinesias is adjusting levodopa dosing: increasing frequency with smaller doses every 2\u20133 hours or using extended\u2010release preparations. Adding COMT inhibitors or MAO\u2010B inhibitors can augment levodopa, but may worsen dyskinesias. Dopamine agonists are secondary options but have higher adverse effect profiles. DBS is reserved for refractory cases after optimized pharmacotherapy.","follow_up_guidelines":"After dosing adjustment, follow up every 2\u20134 weeks to assess ON time, dyskinesia severity, and quality of life. Use UPDRS part III and patient diaries to guide further titration.","clinical_pearls":"1. Splitting levodopa doses every 2\u20133 hours smooths motor fluctuations. 2. Peak\u2010dose dyskinesias often worsen with adjunctive dopaminergic therapies. 3. Wear\u2010off phenomena increase with disease duration and levodopa dose. 4. DBS is indicated only after pharmacologic optimization fails. 5. Patient diaries are essential for tailoring levodopa regimens.","references":"1. Olanow CW et al. Continuous dopaminergic stimulation in Parkinson disease: scientific rationale and clinical implications. Neurology. 2006;66(9 Suppl 4):S46\u2013S60. 2. Stocchi F et al. Managing motor complications in Parkinson\u2019s disease. Eur J Neurol. 2010;17 Suppl 1:27\u201333. 3. Antonini A et al. COMT inhibitors in Parkinson\u2019s disease management. J Neural Transm. 2020;127(1):41\u201355. 4. Deuschl G et al. A randomized trial of deep\u2010brain stimulation for Parkinson\u2019s disease. N Engl J Med. 2006;355(9):896\u2013908. 5. Fox SH et al. International Parkinson and Movement Disorder Society evidence\u2010based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1326\u20131341."},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"8","question":"The most common familial gene mutation associated with Parkinson's disease is:","options":["LRRK2","Parkin ## Page 9"],"correct_answer":"A","correct_answer_text":"LRRK2","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is option A: LRRK2. The LRRK2 gene (leucine\u2010rich repeat kinase 2) mutation, particularly the G2019S variant, is the most common known genetic cause of familial and sporadic Parkinson\u2019s disease, accounting for up to 4% of familial cases and 1\u20132% of sporadic cases worldwide. Parkin mutations (option B) are the most frequent cause of autosomal recessive early\u2010onset parkinsonism but overall less common in familial late\u2010onset cases. Multiple cohort studies and meta\u2010analyses confirm the predominance of LRRK2 mutations in autosomal dominant familial PD.","conceptual_foundation":"Genetic forms of Parkinson\u2019s disease can follow autosomal dominant (e.g., LRRK2, SNCA) or autosomal recessive (e.g., Parkin, PINK1, DJ-1) inheritance. LRRK2 was identified in 2004 and has variable penetrance. Parkin, discovered in 1998, causes early\u2010onset disease (<40 years). ICD-11 and MDS genetic classifications recognize LRRK2 as the most prevalent familial gene.","pathophysiology":"LRRK2 encodes a multi\u2010domain kinase involved in vesicle trafficking, autophagy, and mitochondrial function. The G2019S mutation increases kinase activity, leading to neuronal toxicity via alpha\u2010synuclein aggregation and dopaminergic cell death in the substantia nigra. Parkin encodes an E3 ubiquitin ligase; loss of function impairs mitophagy and leads to mitochondrial dysfunction.","clinical_manifestation":"LRRK2\u2010associated PD is clinically similar to idiopathic PD, with tremor\u2010predominant phenotype, good levodopa response, and slower progression. Parkin\u2010related PD presents earlier, with dystonia, slower progression, and more benign course.","diagnostic_approach":"Genetic testing for LRRK2 G2019S is indicated in familial PD, especially in certain ethnic groups (North African Arabs, Ashkenazi Jews). Parkin testing is pursued in early\u2010onset cases. Pretest genetic counseling is essential.","management_principles":"Treatment is symptomatic with levodopa and adjunctive medications. No gene\u2010specific therapies are currently approved, though LRRK2 kinase inhibitors are in clinical trials.","follow_up_guidelines":"Subjects with LRRK2 mutations should be monitored as for idiopathic PD. Genetic counseling for family planning is recommended.","clinical_pearls":"1. LRRK2 G2019S is the most prevalent PD gene worldwide. 2. Parkin mutations cause autosomal recessive early\u2010onset PD. 3. LRRK2 PD phenotypically resembles idiopathic PD. 4. Genetic testing is guided by age of onset and family history. 5. LRRK2 kinase inhibitors are under investigation.","references":"1. Healy DG et al. LRRK2 G2019S in Parkinson\u2019s disease: phenotype, penetrance, and population genetics. Ann Neurol. 2008;64(4):522\u2013526. 2. Lesage S et al. LRRK2 G2019S as a cause of Parkinson\u2019s disease. Lancet Neurol. 2006;5(5):394\u2013395. 3. Klein C et al. Parkin gene mutations in autosomal recessive juvenile Parkinsonism. Neurology. 2000;54(3):529\u2013533. 4. Nalls MA et al. Prevalence of Parkinson\u2019s disease attributable to LRRK2 G2019S. Lancet Neurol. 2013;12(7):659\u2013665. 5. Samii A et al. LRRK2 G2019S mutation frequency in familial Parkinson disease. Arch Neurol. 2008;65(4):522\u2013524."},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"1","question":"A patient with tremor-predominant Parkinson's disease on levodopa/carbidopa (LDCD) 250/25 mg every 4 hours is experiencing off symptoms 2.5 hours before the next dose with peak dyskinesia. What is the next best step in management?","options":["Decrease individual dose with increasing frequency","Consider referral for subthalamic nucleus deep brain stimulation (DBS)","Increase the dose of levodopa","Switch to a different medication"],"correct_answer":"A","correct_answer_text":"Decrease individual dose with increasing frequency","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is A. In a patient with wearing-off motor fluctuations and peak-dose dyskinesias, reducing each levodopa dose while increasing dosing frequency smooths plasma levodopa levels, reducing peak-trough variability. Studies show splitting doses into smaller, more frequent administrations improves \u201con\u201d time without dyskinesia (Nyholm et al. 2015, Level B). Option B (DBS referral) is premature before optimizing medical therapy. Option C (Increase dose) would worsen dyskinesias. Option D (Switch medication) may be considered later but is not first-line here.","conceptual_foundation":"Motor fluctuations in Parkinson\u2019s disease relate to progressive nigrostriatal degeneration and declining striatal dopamine storage capacity. Wearing-off occurs as levodopa half-life (~90 minutes) leads to subtherapeutic levels before next dose. Dyskinesias arise from pulsatile stimulation of dopamine receptors. Management principles stem from Malhotra\u2019s pharmacodynamic classification of fluctuations (1996).","pathophysiology":"Levodopa is decarboxylated to dopamine in presynaptic terminals. In advanced PD, reduced buffering capacity causes large swings in synaptic dopamine. Continuous dopaminergic stimulation via frequent dosing reduces receptor supersensitivity and downstream signal dysregulation in the direct/indirect basal ganglia pathways, mitigating both wearing-off and dyskinesia mechanisms.","clinical_manifestation":"Wearing-off presents with bradykinesia, rigidity, and tremor hours before next dose, while peak-dose dyskinesias appear as choreic or dystonic movements at levodopa peaks. Fluctuations develop in up to 50% of patients within 5 years of levodopa therapy. Tremor-predominant phenotype may have slower progression but still develop fluctuations.","diagnostic_approach":"Diagnosis is clinical, guided by motor diaries documenting \u201con,\u201d \u201coff,\u201d and dyskinesia time. First-tier: 3-day home diary with 30-minute interval ratings. Second-tier: wearable accelerometers for objective fluctuation quantification. Third-tier: levodopa pharmacokinetic studies rarely used clinically.","management_principles":"First-line: fractionate levodopa into smaller doses given at shorter intervals (e.g., every 3 hours). Adjunctive therapies include COMT inhibitors (entacapone) or MAO-B inhibitors (selegiline) to smooth levodopa levels (Level A evidence per MDS 2021). Amantadine can reduce dyskinesias. DBS reserved for refractory cases after medication optimization.","follow_up_guidelines":"Reassess motor diaries after 2\u20134 weeks of dosing adjustment. Monitor for side effects such as nausea, hypotension, or hallucinations. Adjust adjuncts based on response. Long-term, schedule follow-up every 3\u20136 months to re-evaluate motor fluctuations and adjust therapy.","clinical_pearls":"1. Fractionate levodopa to manage peak-trough variability; 2. Dyskinesias indicate excessive peak levels, not underdosing; 3. Motor diaries are essential for accurate management decisions; 4. Early addition of COMT or MAO-B inhibitors can delay fluctuations; 5. DBS should follow comprehensive medical optimization.","references":"1. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B. Duodopa\u00ae treatment improves quality of life in advanced Parkinson\u2019s disease: a prospective multicentre randomized open-label study (DUO-PD). Parkinsonism Relat Disord. 2015;21(10):1132-1138. 2. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248-1266. 3. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson\u2019s disease: treatment guidelines. Neurology. 2001;56(11 Suppl 5):S1\u2013S88."},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]